Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past decade, according to retrospective ...
Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...
Dr. Mrinal M Gounder emphasizes the complexity of breast cancer and the necessity for unique treatments for its many variants ...
A Professor of Paediatric Clinical Pharmacology, University of Ghana Medical School, Professor George Obeng Adjei, has advocated ...
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC News reported.
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors engaged.
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
The adoption of pharmacists in general practice has resulted in improvements in prescribing quality, study finds ...
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback